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decrease in medical errors; positive ROI and meeting government expectations for 
healthcare reform (including ACO, PCMH, PQRS, MU). ePRO benefits include: over-
coming paper limitations (illegible patient entries, large amounts of missing data, 
easily destroyed, no time/date stamps); more easily integrated; readiness to analyze; 
higher quality data; easier for sites/sponsors to obtain information; increased effi-
ciency; increased compliance; easier to monitor patient safety; decrease in errone-
ous data; reduction in patient/site burden. Most reasons for increased EMR adoption 
in clinical practice are similar to ePRO benefits for clinical research. Major reasons 
for EMR adoption are positive ROI associated with higher quality data and meet-
ing government expectations. Clinical research still needs to recognize the overall 
positive ROI, since start-up costs are higher with ePRO. ePRO can pose an overall 
positive ROI when looking at the costs savings associated with higher quality data. 
While regulatory authorities recognize ePRO benefits, additional regulatory support 
would also render higher ePRO adoption rate.
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BAckground: Systematic reviews (SRs) are critically important to support deci-
sion making in health care. Interest in reliable and quick evidence synthesis has 
sparked development of “rapid reviews” yet no clear consensus exists on what 
these are or what processes they use. The goal of this project was to understand 
and describe practices of conducting rapid reviews. Methods: We searched the 
literature to identify rapid review methods, guidance, and empiric evidence, and 
conducted interviews with organizations that produce rapid reviews to identify 
current practices, and understand the evolution of their programs and products. We 
analyzed the data qualitatively, integrating information gathered from the literature 
and interviews. results: We identified 36 rapid products from 20 organizations 
(production time, 5 minutes to 8 months). Almost all products used four approaches 
to save time (restricted database searching, inclusion criteria, data abstraction, and 
dual review); with faster products tending to employ more of these approaches. 
Methods also varied by synthesis type, with some products (Inventories) avoiding 
synthesis completely, while others (Rapid reviews) performed syntheses similar to 
full reviews but with limited scope and review to achieve deadlines. Interviews with 
producers provided insight into these variations. Most rapid products are produced 
to support specific decisions in an identified timeframe within the context of a 
close relationship between researcher and end-user. This allows selection of meth-
ods that best fit the decision and timeframe, and helps the end-user understand 
resulting limitations. Almost no empiric evidence exist comparing rapid reviews 
and SRs. conclusions: Rapid products have tremendous methodological varia-
tion, but categorization based on timeframe or type of synthesis reveals some pat-
terns. This variation in methods results in part from the close relationship between 
reviewer and end-user. Organizations considering production or consumption of 
rapid review products need to consider this context and other factors.
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resource Modelling: the Missing Piece oF the htA JigsAW?: Within health 
technology assessment (HTA), cost-effectiveness analysis and budget impact analyses 
have been broadly accepted as important components of decision making. However, 
whilst they address efficiency and affordability, the issue of implementation and 
feasibility has been largely ignored. HTA commonly takes place within a deliberative 
framework that captures issues of implementation and feasibility in a qualitative 
manner. Economic analyses typically ignore the short-term constraints (e.g. beds, 
availability of computed tomography scanners, nurses) that might lead to low levels 
of uptake. We argue that only through a formal quantitative assessment of resource 
constraints can these issues be fully addressed. Analyses that do not consider these 
issues run the risk of recommending technologies that cannot be delivered within 
the expected time frame, or which require higher than expected costs to ensure 
delivery thereby reducing the cost effectiveness of the recommendation. We argue 
that resource modelling is required for uptake to be formally considered by decision 
makers. We define resource modelling as a quantitative assessment of technology 
diffusion, its related resource requirements and capacity constraints. Resource mod-
elling is especially useful if there are significant changes in the amount or type of 
resources needed within the pathway by implementing the new technology. We will 
describe the usefulness of resource modelling along with examples from the litera-
ture. We describe the modelling techniques (discrete event simulation and system 
dynamics) which can capture these resource implications and highlight that these 
analyses can be performed at a national or organisational level. Finally, important 
issues that need to be considered when undertaking resource modelling are described 
before setting out recommendations for the use of resource modelling in HTA. Further 
research should examine the potential use of operational research techniques in the 
assessments of cost effectiveness and feasibility.
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This conceptual paper will illustrate the impacts of low quality data, describe the 
requirements of the data cleaning process, compare the data cleaning process for 
paper versus ePRO, and provide recommendations of how ePRO can be implemented 
to decrease the level of effort of data cleaning. Before data can be analyzed, data 
cleaning must occur to ensure high data quality. Low quality data can have major 
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MaRS EXCITE is an innovation in health technology assessment (HTA) where 
industry, academia, and the health system collaborate to design and execute a 
robust evaluation program for innovative medical technologies with high disruptive 
potential that proactively satisfies regulatory and reimbursement decision-mak-
ers requirements. EXCITE compromises five Methodological Centres (MCs) across 
Ontario, Canada with demonstrated excellence in methodologies for designing and 
conducting complex, multi-centre trials and HTAs. The MCs develop the protocol 
collaboratively with industry and experts, and oversee the clinical trials, involv-
ing multiple participating sites. In an attempt to promote consistency in Quality 
Assurance (QA) amongst MCs and participating sites for EXCITE studies, EXCITE 
has developed SOPs, through the Clinical Trials Methodology Committee, that relate 
exclusively to the unique collaboration with the MCs. These were developed through 
an analysis of host institution SOPs and developing overarching SOPs that were 
either unique to the EXCITE QA program, or where deemed appropriate though 
lacking from some host institutions. This harmonization of SOPs across the five 
current EXCITE MCs has allowed EXCITE to address one of the main goals of clinical 
trial QA that is integrity of data. The second goal of clinical trial QA, patient safety, 
is achieved through the Safety Advisory committee, which sets safety standards 
that must be adhered to by the MCs evaluating the technologies. The committee 
reviews all protocols to ensure that patient safety issues are addressed,makes rec-
ommendations for protocol changes as necessary and may also mandate training 
requirements to ensure competency in utilization of any medical technology under-
going testing in the EXCITE program. Therefore, MaRS EXCITE was able to deploy 
a collaborative platform to harmonize the QA processes across five independent 
academic methodological centres in order to conduct efficient and effective clini-
cal trials that are used in evaluating disruptive medical technologies in an effort to 
optimize patient outcomes.
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There is increasing interest in innovation in the development and validation of 
clinical outcome assessments (COAs), fuelled by the need to demonstrate robust 
evidence of content validity for regulatory approval with ever increasing budget 
and time constraints. Traditionally, qualitative research methods have relied upon 
standard one-one interview and focus groups techniques; however these may not 
always be appropriate, particularly for patients with communication difficulties 
or in pediatric populations or for sensitive research areas. Creative methodolo-
gies can be a pragmatic way to elicit patient-driven insights and identify appropri-
ate outcomes in special populations. There is a well-established literature base 
exploring the use of creative methodologies in social research and many of these 
approaches can be readily applied to outcomes research. We have reviewed a vari-
ety of creative methods and purposively selected the most valuable approaches to 
create a toolkit of methods to advance the development of patient-centred COAs. 
The toolkit of creative methods is discussed in context of: 1) disease and clinical 
characteristics, 2) patient demographics and 3) research objectives. Integration of 
creative methodologies throughout the COA development process serves to develop 
patient-driven insights for concept elicitation and item generation. By advancing 
elicitation techniques (e.g. visual elicitation), and ecological evidence generation 
(e.g. video diaries) participants’ have the power and freedom to show how they per-
ceive and experience their condition, rather than reliance on verbal report. Creative 
methodologies can be used to demonstrate reliable, valid and content rich data 
for a variety of populations and contexts of use. There are exciting opportunities 
to build upon existing practice and advance creative research approaches in this 
field. Integrating such methodologies generates patient insight to underpin content 
development for COAs ensuring they are developed with an evolving fit for pur-
pose approach. The application of such methods for regulatory COA development 
requires further exploration.
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In clinical practice, Electronic Medical Record (EMR) adoption has rapidly increased 
over recent years. In 2013, it was estimated that 78.4% of physician-based practices 
use some type of EMR system (as reported by National Center for Health Statistics). 
In clinical research, electronic Patient Reported Outcomes (ePRO) adoption is mov-
ing slower–where it is estimated that less than half of PRO studies use ePRO. This 
conceptual paper compares EMR benefits of clinical practice with ePRO benefits of 
clinical research and provides recommendations of how clinical research can follow 
clinical practice in benefiting from technology. EMR benefits include: overcoming 
paper limitations (illegible clinician notes, large amounts of missing information, 
easily destroyed, no time/date traceability and whose viewed/accessed); improved 
integrations with other practices/facilities; readiness to analyze; higher quality data; 
easier to obtain payment; easier to provide information to insurance providers; 
increased efficiency; increased compliance; increased quality of care/patient safety; 
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A37
how the concept and principles of software engineering and adopting their best 
practices in model development can increase model transparency and our confi-
dence that our models perform as expected. We will also compare the advantages 
and disadvantages of using spreadsheets versus other programming languages. 
Briefly, the primary advantage of the spreadsheet is that it’s universally available 
and accessible to all. It’s universal in that a spreadsheet is available on most com-
puters. It’s accessible in that everyone can open the model, inspect it, and use it. 
Beyond these advantages, the structure of the spreadsheet challenges our model 
code to be intention revealing and transparent. For example, generating an audit 
trail showing the history of what changes were made, when, and by who is not 
possible with spreadsheet files. Moreover, the spreadsheet does not have available 
standard software tools for developing test suites. A test suite represents a series 
of tests that must be passed to confirm software performs as expected. For models, 
this would mean the test suite confirms a model computes what it purports to com-
pute. Hence, test suites serve a critical and foundational function in the lifecycle of 
modern software development and can serve a similar role in pharmacoeconomic 
model development. In summary, adopting traditional programming languages and 
their software engineering support tools offers an opportunity to increase model 
transparency compared with spreadsheets. Reimbursement agencies should con-
sider broadening their software guidances to include non-spreadsheet programming 
languages to increase model transparency and our confidence that pharmacoeco-
nomic models perform as expected.
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The end product of EQ-5D valuation studies is an algorithm describing, on aver-
age, the utility decrements associated with each dimension and level of problems 
within the EQ-5D descriptive system, and potentially a range of interaction effects 
between dimensions and levels. Standard methods for eliciting the preference data 
upon which these algorithms are based (time trade-off, discrete choice experiment, 
standard gamble, visual analogue scale) vary considerably in approach, but have 
in common an aim to ‘uncover’ these preferences by asking survey respondents to 
evaluate a sub-set of EQ-5D health states, and then using their responses to infer 
the relative importance to them of the specific dimensions and levels. An alterna-
tive approach, which has never been explored, is to directly ask people to construct 
their own personal utility functions. Instead of asking people to value a selection of 
EQ-5D states, and to infer their utility functions with respect to EQ-5D dimensions 
and levels from their responses, this approach involves directly asking people about 
the relative importance to them of dimensions, levels and interactions between 
them. In this presentation, we will describe the development of an innovative set 
of questions designed to directly elicit personal utility functions from members of 
the general public. The approach is informed by “swing weighting” techniques in the 
multi-criteria decision analysis literature and by existing direct valuation methods 
such as the short form individual quality of life measure. We will summarise the 
results of a feasibility study which tested the acceptability of the questions, and will 
show how the results can be used to generate EQ-5D values. We will also discuss the 
research that is required to further refine and operationalise the method.
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oBJectives: Cardiac rhythm management devices (CRMD’s) have proven their clini-
cal effectiveness for patients with heart rhythm disorders. Little is known about safety 
and complication rates during implantations of these devices. This study demon-
strated the major ant the minor complications related to implantations of CRMD’s, 
and estimated the additional hospital stay and cost associated with managing these 
adverse events. Methods: During a period of one year in total 464 consecutive recipi-
ents were subjected to CRMD’s implantation and furthermore were recruited and 
followed up for 2 years. Finally, data were analyzed for 398 patients who completed 
the two year’s follow up, resulting in a total of 796 patient-years. results: From the 
201 patients with initial pacemaker (PM) implantations, 6 (2,99 %) patients had seven 
adverse events, six major and one minor (5 patients had lead’s dislodgement, 1 of 
them twice (minor adverse events) and 1 patient developed pocket infection (major 
adverse event)), while from the 117 PMs replacements 1 (0,85 %) patient developed 
a major adverse event a pocket erosion. 2 patients with minor adverse event (1 with 
an initial PM and 1 with replacement) died before they complete the follow up from 
reasons unrelated to cardiac causes. There weren’t any adverse event neither in 
initial implantations (69 patients) nor in replacements (11 patients) of implantable 
cardioverter defibrillator (ICD). The average prolongation of the hospital stay was 7 
days ranging from 1 to 35 days, resulting in 17.411 € of total additional direct hospital 
cost. conclusions: This study provides relatively low rates of adverse events in 
impacts on data analysis/results along with cost impact. As estimated by the Data 
Warehousing Institute, the costs of low quality data exceeds $600 billion annually. 
Data cleaning process includes querying for errors, typos, outliers, out-of-range 
responses, missing data, deviations, etc. Paper: query data for erroneous/out-of 
range values; these values need to be cross-checked with original paper form to 
identify if error is associated with patient entry or data entry staff. If associated with 
patient entry, it may need to be set as missing. When original paper is lost, values 
may need to be set to missing as accuracy cannot be confirmed. Time/dates may be 
out-of-range or missing, which require cross-checking with original paper. If time/
date cannot be confirmed, the entire entry may need to be set as missing. Missing 
values in data need to be identified and cross-checked with original paper to confirm 
if value was skipped by patient or by data entry staff. ePRO: can be implemented to 
prevent entry of out-of range values; includes time/date stamps; patient direct data 
entry eliminates error by data entry staff; can be programmed to not allow skipped 
responses to prevent missing data responses. End-of-study time is precious to the 
pharma industry where results need to be analyzed for submissions. Data cleaning 
with paper can be labor intensive and ePRO can save time with preventing errors 
from occurring, reducing time needed for data cleaning.
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oBJectives: The global economic crisis imposes severe restrictions on healthcare 
budgets, limiting the coverage of new interventions, even when they are cost-effec-
tive. Our objective was to develop a tool that can assist decision-makers in compar-
ing the impact of medical intervention alternatives on the entire target population, 
under a pre-specified budget constraint. Methods: We illustrated the tool by using 
a target population of 1,000 patients, and a budget constraint of $1,000,000. We com-
pared two intervention alternatives: the current practice that costs $1,000 and adds 
0.5 quality-adjusted-life-years (QALYs) per patient and a new technology that costs 
100% more, and provides 20% more QALYs per patient. We also developed a formula 
for defining the maximum premium price for a higher-cost/higher-effectiveness 
intervention that can justify its adoption under a constrained budget. results: 
Using the new therapy will result in a loss of 300 QALYs, compared to the lower-
cost, lower-effective intervention, despite a favorable incremental cost-effectiveness 
ratio (ICER) of $10,000. The maximum price for the higher-efficacy therapy that 
will preserve the target population outcomes is 20% higher than the lower-cost 
therapy. conclusions: Although an intervention associated with higher costs 
and higher efficacy may have an acceptable ICER, it could provide inferior outcomes 
in the target population under budget constraints, depending on the relative effec-
tiveness and costs of the interventions. The cost premium that can be justified for 
a higher-efficacy intervention is directly correlated to its effectiveness premium. 
Using the proposed tool may assist decision-makers in improving overall healthcare 
outcomes, especially in times of economic downturn.
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While some have fully embraced and incorporated ePROs/eCOAs into protocol 
designs, many continue to use paper PROs/COAs. This conceptual paper explores rea-
sons for paper PRO/COA continued use, focusing on how PROs can be integrated into 
the electronic trial solution to reduce the burden to patients/participants, sites, and 
clinical teams in setting up, maintaining, and closing out a clinical trial. Associated 
risks and mitigation strategies will be identified in transitioning to ePRO/eCOA 
collection modes. Strategies recommended for successful transition to integrated 
electronic PRO/COA solutions will be discussed. Integration of ePRO/eCOA provides 
several benefits over paper, including improved compliance and higher data quality. 
Comparing the advantages of electronically captured PRO/COA data vs. paper, the 
benefits of ePRO/eCOA far outweigh those of paper. Combine this with the support 
and advocacy of ePRO/eCOA in clinical trials by regulatory authorities and a shift of 
the general population towards electronic devices; it raises the question why all clini-
cal trials are not using ePRO/eCOA to optimize the integrity of data and trial results. 
Common obstacles in the selection of a PRO/COA electronic data collection mode 
include: paper instruments designed for a paper world, inability to determine true 
risks, unknown total cost of electronic vs. paper administration, instrument author 
has sometimes costly requirements for migration, unclear translation expectations, 
and fear of the unknown. An assessment of methods to facilitate the transition to 
electronic data capture will be performed. Examples include use of items/instruments 
that are appropriate for electronic platforms and easily migrated and site and patient 
training plans. In this age of technological advancements, including an integration 
plan in clinical trials is important to mitigate potential risks and minimize the burden 
to clinical trial staff and participants. Detailing this up front can help to alleviate many 
of the obstacles in the transition from paper to electronic PRO/COA.
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The spreadsheet dominates the pharmacoeconomics field as the software platform 
of choice for programming pharmacoeconomic models that are submitted to reim-
bursement agencies worldwide. Arguably, the spreadsheet represents a poor choice 
for model development and implementation as standard software development 
tools to manage spreadsheet quality are non-existent. This paper will demonstrate 
